Date: 2011-06-24
Type of information: Capital increase
Company: Neovacs (France)
Investors: The shares were placed with 3 investors.
Amount: € 420 000
Funding type: capital increase via the issuance independent of preemption rights of 105,500 shares.
Planned used:
Others: Neovacs has announced the close of a private capital increase undertaken on 23rd June. This capital increase was in response to additional demand from institutional investors, notably from outside France. The capital increase took place via the issuance independent of preemption rights of 105,500 shares (Issue price : € 4 (€ 3.85 over par value).
Therapeutic area: Autoimmune diseases – Inflammatory diseases - Rheumatic diseases
